Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics

Highlights This study demonstrates that initiation of glucagon‐like peptide‐1 receptor agonists among individuals with type 2 diabetes (T2D), including those with concomitant atherosclerotic cardiovascular disease (ASCVD), has remained low in the United States between 2014 and 2019, despite clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingvay, Ildiko, Aroda, Vanita R., Honoré, Julie Broe, Ersbøll, Anne S., Nystrup Husemoen, Lise Lotte, Jensen, Anders Boeck, Sommer Matthiessen, Kasper, Kosiborod, Mikhail Naum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934953/
https://www.ncbi.nlm.nih.gov/pubmed/36796312
http://dx.doi.org/10.1111/1753-0407.13363
Descripción
Sumario:Highlights This study demonstrates that initiation of glucagon‐like peptide‐1 receptor agonists among individuals with type 2 diabetes (T2D), including those with concomitant atherosclerotic cardiovascular disease (ASCVD), has remained low in the United States between 2014 and 2019, despite clinical evidence supporting their use for cardiovascular risk reduction. These findings add to the existing literature to highlight a gap in adherence to current practice guidelines, which suggests that most patients with T2D and ASCVD in the United States may not be receiving optimal risk‐reducing therapies.

Ejemplares similares